Introduction Over 100 genetic variants associated with rheumatoid arthritis (RA) to date explain a relatively small proportion of its heritability. Epigenetic factors, including variation in DNA methylation, may in part account for this, impacting gene expression at a cellular level. Objectives Seeking insights into disease pathogenesis and discriminatory biomarkers of clinical value, we undertook an epigenome-wide association study (EWAS) of DNA methylation in CD4 +T cells of untreated RA and control patients attending a UK early arthritis clinic. Methods A cohort of 44 treatment-naive RA patients were recruited from the Newcastle Early Arthritis Clinic (NEAC) along with a comparator cohort of 53 matched disease controls with arthritis. CD4 +T cells were isolated from fresh peripheral blood by positive selection, and DNA/RNA extracted from lysates. DNA methylation was quantified on the Illumina Human MethylationEPIC array, and gene expression measured using the Illumina 12HT BeadChip. Following methylation data pre-processing, functional normalisation and probe filtering, 715,279 CpGs were considered. Batch effects were corrected using the ComBat function and a moderated T-statistic identified differentially methylated positions (DMPs) between RA patients and disease controls. Differentially methylated regions (DMRs; clusters of DMPs) were also sought using the DMRcate function. Linear Discriminant Analysis (LDA) combined with a Stepwise Forward Selection (SFS) procedure was used to identify the most discriminatory CpGs for downstream independent validation. Results Between RA and non-RA patients we identified a total of 263 DMPs in CD4 +T cells, of which 159 were hypomethylated in RA patients (adjusted p-value<0.05, Db>5%), as well as 14 DMRs. One DMR in particular, comprising 4 intronic CpG sites in the CD151 gene that were hypomethylated in RA patient CD4 +T cells, was notable for the strong association between CD151 expression and methylation. This suggests a mechanism whereby altered DNA methylation during early disease determines pathogenically relevant gene expression. We assessed the ability of our differentially-methylated CpG sites to discriminate patients by diagnosis through evaluating the performance of a classification algorithm. LDA classification based on CpGs selected by SFS achieved an area under the receiver operating characteristic (ROC) curve of 0.82 (95% confidence interval: 0.80-0.85).
Conclusions The CD4 +T cell methylation landscape in ageand sex-matched early inflammatory arthritis patients has unique features in early RA, indicating a possible role for DNA methylation in conferring susceptibility to this condition. A further application of these data may be in predicting outcome in undifferentiated arthritis, though further work is required to explore this.
Disclosure of interest None declared
Introduction Osteoarthritis (OA) is an age-related musculoskeletal disease and the most common form of arthritis characterised by low grade synovial inflammation and articular cartilage degeneration. OA has many risk factors such as genetic predisposition, age and gender, but also joint specific (e.g. trauma) and systemic (obesity, hormones). Also many different cell types have been implicated in the pathogenesis of OA and interplay between these cells contribute to the dynamic events associated with disease. Recently, extracellular vesicles (EVs) have emerged as mediators of intercellular communication. There is however very little known about the pathophysiological role of EVs in musculoskeletal diseases. In this study, we investigate whether plasma EVs from OA patients can drive chondrocyte terminal differentiation, a pathophysiological process observed in affected joints and a hallmark of OA. Objectives Study the effect of plasma-derived EVs from OA patients during chondrogenenic differentiation of mesenchymal stem cells. Methods Plasma-derived extracellular vesicles (pEVs) were isolated from plasma of OA patients and age-matched healthy controls using size-exclusion chromatography. EV containing fractions were characterised according to ISEV guidelines. 1 Pelleted MSCs were stimulated with TGF-b and BMP-2 to induce chondrogenic differentiation, either in the presence of pEVs isolated from OA patients or healthy controls. After 8 days, RNA was isolated and RT-qPCR was performed to determine the gene expression profiles. Results No significant difference was observed in particle concentration, size or protein concentration between OA patients and age-matched controls. In the presence of pEVs from OA patients MSC-derived chondrocytes showed a significant increase in the expression of MMP13 (6.1-fold), RUNX2 (1.9-fold) and RANKL (2.3-fold), compared to pEVs from healthy controls. A trend towards higher ADAMTS5 expression (2.5-fold, p=0.0685) with OA pEVs was also observed. Additionally, we found significantly higher expression of WISP1 (24-fold), suggesting activation of Wnt signalling. All other proinflammatory genes tested were not significantly different between the two groups. Conclusions Here, we show direct evidence that circulating pEVs from OA patients can enhance OA-related genes, like MMP13, in MSC-derived chondrocytes. The expression profile found suggest the presence of Wnt-proteins on pEVs from OA patients, which are known to be involved in cartilage development and can induce chondrocyte hypertrophy, and we previously have shown that WISP-1 expression is a feature of experimental and human OA. 2 We showed that pEVs can transfer disease-related phenotypic changes and this might implicate them in the pathophysiological process of OA.
